Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
experimental group:Nebulized inhalation of homoharringtonine+Basic treatment
control group:Basic treatment
Sponsors
Beijing Ditan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 50 years; 2. RT-PCR method detects the positive of new coronavirus nucleic acid; 3. The time between the first positive nucleic acid test or the first appearance of clinical symptoms is no more than 5 days after enrollment; 4. The informed consent form has been signed.
Exclusion criteria
Exclusion criteria: 1. Known or suspected allergy to the components of homoharringtonine; 2. According to the current trial implementation of the latest version of the "New Coronavirus Infection Pneumonia Diagnosis and Treatment Plan", the patient is diagnosed as a critically ill patient with novel coronavirus pneumonia; 3. Combined with severe liver disease (TBIL >= 2 ULN, ALT, AST >=5 ULN; 4. Patients with severe renal insufficiency (glomerular filtration rate <= 60 mL/min/1.73m2) or who are receiving continuous renal replacement therapy, hemodialysis, and peritoneal dialysis; 5. Patients who have severe breathing difficulties and cannot complete the self-aerosolized drug inhalation; 6. Patients with hematological tumors; 7. Patients who have used antiviral drugs in the past 2 months, such as interferon, lopinavir, ritonavir, remdesivir, etc., are receiving other antiviral drugs; 8. Women who are pregnant or breastfeeding or have a birth plan during the trial period and within 6 months after the end of the trial; 9. Are participating in other clinical trials or are using experimental drugs; 10. Rehabilitation plasma therapy for patients with COVID-19; 11. Are using Chinese medicine for treatment; 12. Patients with diabetes, hypertension and obese people; 13. According to the judgment of the investigator, there are other circumstances that are not suitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral load; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ratio of light to ordinary to heavy duty;Proportion of heavy to critical loads;Time of nucleic acid negative reaction of novel coronavirus; | — |
Countries
China
Contacts
Public ContactZhang Fujie
Beijing Ditan Hospital, Capital Medical University
Outcome results
None listed